Xconomy: Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More
bluebird bio completes spin-off of cell therapy company 2seventy bio | Seeking Alpha
Why Bluebird Bio Stock Is Sinking This Week | The Motley Fool
Why Bluebird Bio Stock Is Taking Flight Today | The Motley Fool
Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US | Fierce Pharma
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
Bluebird bio CMO quits amid a roller coaster year and upcoming split | Fierce Biotech
Bluebird Bio sees Europe as first market for its gene therapies | Fierce Biotech
Pfizer Is in Talks to Buy Sickle-Cell Drugmaker, WSJ Reports - Bloomberg
Code of Business Conduct and Ethics
Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | The Motley Fool
AavantiBio snags another bluebird bio VP with gene therapy chops as 6th executive hire this year | Fierce Biotech
bluebird bio Inc., Undervalued Acquisition Candidate (NASDAQ:BLUE) | Seeking Alpha
Five things for pharma marketers to know: Monday, August 6, 2018 - MM+M - Medical Marketing and Media
Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US | Fierce Pharma
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
bluebird bio: A Speculative Buy With Extraordinary Upside Potential (BLUE) | Seeking Alpha
Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech - TheStreet
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches | Fierce Pharma
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? | The Motley Fool
bluebird bio: Returning To A Previous Winner (NASDAQ:BLUE) | Seeking Alpha
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
StockWatch: After Bluebird's Second Approval, Investors Are Looking for More
BLUEBIRD BIO, INC. : BLUE Stock Price | US09609G1004 | MarketScreener
